Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases

Hiroyuki Aiba; Takanori Funaki; Masaki Yamada; Kozue Miyake; Saki Ueno; Chiaki Tao; Shota Myojin; Toshihiro Matsui; Chikara Ogimi; Hitoshi Kato; Isao Miyairi; Kensuke Shoji

doi:10.1016/j.jiac.2023.09.025

Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases

J Infect Chemother. 2024 Feb;30(2):176-178. doi: 10.1016/j.jiac.2023.09.025. Epub 2023 Sep 27.

Authors

Affiliations

¹ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.
² Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan; Department for Advanced Medicine for Viral Infections, National Center for Child Health and Development, Tokyo, Japan.
³ Department of Clinical Research Promotion, National Center for Child Health and Development, Tokyo, Japan.
⁴ National Center for Child Health and Development, Tokyo, Japan.
⁵ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan; Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.
⁶ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan. Electronic address: shoji-k@ncchd.go.jp.

PMID: 37769991
DOI: 10.1016/j.jiac.2023.09.025

Abstract

There are few reports on the association between antipyretic use and antibody titers in adolescents and young adults following SARS-CoV-2 vaccination. Multivariable linear regression analyses were performed to examine the association between antipyretic use and antibody titers. The use of antipyretics was not associated with antibody titers (β coefficient [95% CI] = -0.107 [-0.438 to 0.224]).

Keywords: Antibody titers; Antipyretics; BNT162b2; Children; SARS-CoV-2 vaccine.

Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

MeSH terms

Adolescent
Antibodies, Viral
Antipyretics*
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2
Young Adult

Substances

COVID-19 Vaccines
BNT162 Vaccine
Antipyretics
Antibodies, Viral